{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:35:18Z","timestamp":1791588918961,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01437-8","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T23:38:32Z","timestamp":1747265912000},"page":"1705-1718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature"],"prefix":"10.1007","volume":"15","author":[{"given":"Gaetano","family":"Licata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6174","authenticated-orcid":false,"given":"Mariachiara","family":"Arisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina Mariarosaria","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Ariasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Tomasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Soglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mezzana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia Linda","family":"Artelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"1437_CR1","doi-asserted-by":"crossref","unstructured":"Liang J, Li W, Liu W, Yu Y, Ye H, Zhang X. Abrocitinib monotherapy for refractory prurigo nodularis: report of two successful cases. Clin Cosmet Investig Dermatol. 2024;17:1793\u20137.","DOI":"10.2147\/CCID.S470641"},{"issue":"17","key":"1437_CR2","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"S Kwatra","year":"2023","unstructured":"Kwatra S, St\u00e4nder S, Bissonnette R, et al. Phase\u00a03 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579\u201389.","journal-title":"N Engl J Med"},{"issue":"12","key":"1437_CR3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1080\/14712598.2021.1958777","volume":"21","author":"S M\u00fcller","year":"2021","unstructured":"M\u00fcller S, Bieber T, St\u00e4nder S. Therapeutic potential of biologics in prurigo nodularis. Expert Opin Biol Ther. 2021;21(12):1577\u201388. https:\/\/doi.org\/10.1080\/14712598.2021.1958777.","journal-title":"Expert Opin Biol Ther"},{"key":"1437_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","volume":"25","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Mendes-Bastos P, St\u00e4nder S. Chronic prurigo including prurigo nodularis: new insights and treatments. Am J Clin Dermatol. 2024;25:15\u201333. https:\/\/doi.org\/10.1007\/s40257-023-00818-z.","journal-title":"Am J Clin Dermatol"},{"key":"1437_CR5","doi-asserted-by":"crossref","unstructured":"Ortiz de Frutos J, Serra Baldrich E, Trib\u00f3 Boixareu MJ, et al. Consensus on the diagnostic algorithm for chronic nodular prurigo. Actas Dermosifiliogr. 2024;115:T967\u201373.","DOI":"10.1016\/j.ad.2024.09.011"},{"key":"1437_CR6","doi-asserted-by":"crossref","unstructured":"Kwatra SG, St\u00e4nder S, Yosipovitch G, Kim BS, Levit NA, O'Malley JT. Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type\u00a02 inflammation. J Investig Dermatol. 2025;145(2):249\u201356.","DOI":"10.1016\/j.jid.2024.06.1276"},{"issue":"5","key":"1437_CR7","first-page":"E11","volume":"112","author":"M Hanly","year":"2023","unstructured":"Hanly M, Watsky KL. Prurigo nodularis: moving forward. Cutis. 2023;112(5):E11\u20134.","journal-title":"Cutis"},{"key":"1437_CR8","doi-asserted-by":"crossref","unstructured":"Kwatra S, Bordeaux ZA, Parthasarathy V, et al. Efficacy and safety of abrocitinib in prurigo nodularis and chronic pruritus of unknown origin: a nonrandomized controlled trial. JAMA Dermatol. 2024;160(7):717\u201324.","DOI":"10.1001\/jamadermatol.2024.1464"},{"issue":"1","key":"1437_CR9","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202301529R","volume":"38","author":"T Komori","year":"2024","unstructured":"Komori T, et al. Hisaoka T, Kotaki A, et al. Blockade of OSMR\u03b2 signaling ameliorates skin lesions in a mouse model of human atopic dermatitis. FASEB J. 2024;38(1):e23359. https:\/\/doi.org\/10.1096\/fj.202301529R.","journal-title":"FASEB J"},{"key":"1437_CR10","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Kim BS, Kwatra SG, et al. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: pooled results from 2 phase\u00a03 trials (LIBERTY-PN PRIME and PRIME2). JAAD Int. 2024;16:163\u201374.","DOI":"10.1016\/j.jdin.2024.03.025"},{"key":"1437_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100281","volume":"4","author":"A Bao","year":"2024","unstructured":"Bao A, Ma E, Cornman H, et al. Dupilumab therapy modulates circulating inflammatory mediators in patients with prurigo nodularis. JID Innov. 2024;4:100281. https:\/\/doi.org\/10.1016\/j.xjidi.2024.100281.","journal-title":"JID Innov"},{"key":"1437_CR12","doi-asserted-by":"publisher","unstructured":"St\u00e4nder S, OLYMPIA 1 Investigators. Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical phase\u00a03 trial. JAMA Dermatol. 2025;161(2):147\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4796.","DOI":"10.1001\/jamadermatol.2024.4796"},{"issue":"2","key":"1437_CR13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78761","volume":"17","author":"K Sinha","year":"2025","unstructured":"Sinha K, Sinha T, Muppa N, et al. Efficacy and safety of nemolizumab in patients with prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2025;17(2):e78761. https:\/\/doi.org\/10.7759\/cureus.78761.","journal-title":"Cureus"},{"key":"1437_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101826","volume":"57","author":"H Sofen","year":"2023","unstructured":"Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin\u00a0M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase\u00a02a study. EClinicalMedicine. 2023;57:101826. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101826.","journal-title":"EClinicalMedicine"},{"key":"1437_CR15","doi-asserted-by":"crossref","unstructured":"Muntaner-Virgili C, Moreno-Vilchez C, Torrecilla-Vall-Llossera C, Figueras-Nart I. Upadacitinib for prurigo nodularis. JAAD Case Rep. 2023;48:131\u20133.","DOI":"10.1016\/j.jdcr.2023.01.037"},{"issue":"5","key":"1437_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4168\/aair.2024.16.5.546","volume":"16","author":"J Lee","year":"2024","unstructured":"Lee J, Kim Y, Shin K, et al. Treatment with upadacitinib in refractory prurigo nodularis: a prospective cohort study. Allergy Asthma Immunol Res. 2024;16(5):546\u201354. https:\/\/doi.org\/10.4168\/aair.2024.16.5.546.","journal-title":"Allergy Asthma Immunol Res"},{"key":"1437_CR17","doi-asserted-by":"publisher","unstructured":"Pezzolo E, Narcisi A, Gargiulo L, et al. Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: a multicenter case series study. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.06.094.","DOI":"10.1016\/j.jaad.2024.06.094"},{"key":"1437_CR18","unstructured":"Kwatra SG, et al. Efficacy and safety of oral povorcitinib in patients with prurigo nodularis: 40-week results from a randomized, double-blind, placebo-controlled phase\u00a02 study. Presentation #D2T01.3F, EADV 2024."},{"key":"1437_CR19","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_1017_2024","author":"K Sardana","year":"2025","unstructured":"Sardana K, Mathachan SR, Muddebihal A, Agrawal D, Ahuja A. Translating tissue expression of STAT1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib\u2014a prospective single-arm investigational study. Indian J Dermatol Venereol Leprol. 2025. https:\/\/doi.org\/10.25259\/IJDVL_1017_2024.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1437_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/12034754251320633","author":"S Sood","year":"2025","unstructured":"Sood S, Geng RSQ, Heung M, et al. Management of chronic prurigo and prurigo nodularis with systemic Janus kinase inhibitors: an evidence-based review. J Cutan Med Surg. 2025. https:\/\/doi.org\/10.1177\/12034754251320633.","journal-title":"J Cutan Med Surg"},{"key":"1437_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","volume":"25","author":"M Croft","year":"2024","unstructured":"Croft M, Islam MN, Aditya GP, et al. OX40 in the pathogenesis of atopic dermatitis\u2014a new therapeutic target. Am J Clin Dermatol. 2024;25:447\u201361.","journal-title":"Am J Clin Dermatol"},{"key":"1437_CR22","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1007\/s13555-024-01308-8","volume":"14","author":"A Abdelhalim","year":"2024","unstructured":"Abdelhalim A, Yilmaz O, Elshaikh Berair M, Torres T. A narrative review of the OX40\u2013OX40L pathway as a potential therapeutic target in atopic dermatitis: focus on rocatinlimab and amlitelimab. Dermatol Ther (Heidelb). 2024;14:3197\u2013210.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1437_CR23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","volume":"190","author":"W Liao","year":"2024","unstructured":"Liao W, Cornman HL, Ma E, Kwatra SG. Prurigo nodularis: new insights into pathogenesis and novel therapeutics. Br J Dermatol. 2024;190:798\u2013810. https:\/\/doi.org\/10.1093\/bjd\/ljae052.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1437_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaad.2020.03.049","volume":"83","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83(1):39\u201345.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1437_CR25","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1038\/s41598-024-58013-x","volume":"14","author":"HL Cornman","year":"2024","unstructured":"Cornman HL, Manjunath J, Reddy SV, et al. Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in type\u00a02 inflammation. Sci Rep. 2024;14(1):8098. https:\/\/doi.org\/10.1038\/s41598-024-58013-x.","journal-title":"Sci Rep"},{"key":"1437_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdin.2023.06.005","volume":"13","author":"YW Yew","year":"2023","unstructured":"Yew YW, Yeo PM. Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore. JAAD Int. 2023;13:13\u20134. https:\/\/doi.org\/10.1016\/j.jdin.2023.06.005.","journal-title":"JAAD Int"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01437-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01437-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T06:00:37Z","timestamp":1748671237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01437-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01437-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not conflict of interest to declare. Gaetano Licata, Mariachiara Arisi, Caterina Mariarosaria Giorgio, Cesare Ariasi, Cesare Tomasi, Simone Soglia, Sara Mezzana, Benedetta Galli, Grazia Linda Artelli, and Mariateresa Rossi have nothing to disclose. Mariateresa Rossi is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Mariateresa Rossi was not involved in the selection of peer reviewers for the manuscript nor of the subsequent editorial decisions. Cecilia Catapano has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The patient in this manuscript has given written informed consent to publication of her case details and clinical photographs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}